Indivior Pharmaceuticals, Inc 6-K, filed Nov 20, 2023
Indivior Pharmaceuticals, Inc. (INDV)
6-K
2023-11-20
For: 2023-11-20
View Original
Added on
July 07, 2026
About this 6-K
Indivior Pharmaceuticals, Inc filed this 6-K on November 20, 2023.
|
|
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
________________________
Washington, D.C. 20549
_____________________
FORM 6-K
_____________________
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934
Date: November 20, 2023
Commission File Number: 001-37835
________________________________________
Indivior PLC
________________________________________
10710 Midlothian Turnpike, Suite 125
North Chesterfield, Virginia 23235
(Address of principal executive office)
_______________________________
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F
Form
20-F ☒ Form 40-F ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ☐
|
|
EXHIBIT INDEX
|
Exhibit
No.
|
Description
of Exhibit
|
|
99.1
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
|
Indivior PLC
|
|
Date: November 20,
2023
|
/s/
Kathryn Hudson
|
|
|
Name:
Kathryn Hudson
|
|
|
Title:
Company Secretary
|
Exhibit
99.1
TR-1: Standard form for notification of major holding
1. Issuer Details
ISIN
|
GB00BN4HT335
|
Issuer Name
|
INDIVIOR PLC
|
UK or Non-UK Issuer
|
UK
|
2. Reason for Notification
|
An acquisition or disposal of voting rights; An acquisition or
disposal of financial instruments
|
3. Details of person subject to the notification
obligation
Name
|
The Goldman Sachs Group, Inc.
|
City of registered office (if applicable)
|
Wilmington, Delaware
|
Country of registered office (if applicable)
|
USA
|
4. Details of the shareholder
Full name of shareholder(s) if different from the person(s) subject
to the notification obligation, above
|
|
City of registered office (if applicable)
|
|
Country of registered office (if applicable)
|
|
5. Date on which the threshold was crossed or reached
|
15-Nov-2023
|
6. Date on which Issuer notified
|
17-Nov-2023
|
7. Total positions of person(s) subject to the notification
obligation
|
|
%
of voting rights attached to shares (total of 8.A)
|
%
of voting rights through financial instruments (total of 8.B 1 +
8.B 2)
|
Total
of both in % (8.A + 8.B)
|
Total
number of voting rights held in issuer
|
|
Resulting situation
on the date on which threshold was crossed or reached
|
0.041362
|
0.014663
|
0.056025
|
77281
|
|
Position of
previous notification (if applicable)
|
0.150099
|
4.998967
|
5.149066
|
|
8. Notified details of the resulting situation on the date on which
the threshold was crossed or reached
8A. Voting rights attached to shares
|
Class/Type of shares ISIN code(if possible)
|
Number of direct voting rights (DTR5.1)
|
Number of indirect voting rights (DTR5.2.1)
|
% of direct voting rights (DTR5.1)
|
% of indirect voting rights (DTR5.2.1)
|
|
GB00BN4HT335
|
|
57055
|
|
0.041362
|
|
Sub
Total 8.A
|
57055
|
0.041362%
|
||
8B1. Financial Instruments according to (DTR5.3.1R.(1)
(a))
|
Type of financial instrument
|
Expiration date
|
Exercise/conversion period
|
Number of voting rights that may be acquired if the instrument is
exercised/converted
|
% of voting rights
|
|
Securities
Lending
|
Open
|
|
20226
|
0.014663
|
|
Sub
Total 8.B1
|
|
20226
|
0.014663%
|
|
8B2. Financial Instruments with similar economic effect according
to (DTR5.3.1R.(1) (b))
|
Type of financial instrument
|
Expiration date
|
Exercise/conversion period
|
Physical or cash settlement
|
Number of voting rights
|
% of voting rights
|
|
|
|
|
|
|
|
|
Sub
Total 8.B2
|
|
|
|
||
9. Information in relation to the person subject to the
notification obligation
|
2. Full chain of controlled undertakings through which the voting
rights and/or the financial instruments are effectively held
starting with the ultimate controlling natural person or legal
entities (please add additional rows as necessary)
|
|
Ultimate controlling person
|
Name of controlled undertaking
|
% of voting rights if it equals or is higher than the notifiable
threshold
|
% of voting rights through financial instruments if it equals or is
higher than the notifiable threshold
|
Total of both if it equals or is higher than the notifiable
threshold
|
|
The
Goldman Sachs Group, Inc. (Chain 1)
|
|
|
|
|
|
The
Goldman Sachs Group, Inc. (Chain 1)
|
GSAM
Holdings LLC
|
|
|
|
|
The
Goldman Sachs Group, Inc. (Chain 1)
|
Goldman
Sachs Asset Management, L.P.
|
|
|
|
|
The
Goldman Sachs Group, Inc. (Chain 2)
|
|
|
|
|
|
The
Goldman Sachs Group, Inc. (Chain 2)
|
Folio
Financial, Inc.
|
|
|
|
|
The
Goldman Sachs Group, Inc. (Chain 2)
|
Folio
Investments Inc.
|
|
|
|
|
The
Goldman Sachs Group, Inc. (Chain 3)
|
|
|
|
|
|
The
Goldman Sachs Group, Inc. (Chain 3)
|
The
Goldman Sachs Group, Inc.
|
|
|
|
|
The
Goldman Sachs Group, Inc. (Chain 3)
|
Goldman
Sachs Bank USA
|
|
|
|
|
The
Goldman Sachs Group, Inc. (Chain 3)
|
Goldman
Sachs Bank Europe SE
|
|
|
|
|
The
Goldman Sachs Group, Inc. (Chain 4)
|
|
|
|
|
|
The
Goldman Sachs Group, Inc. (Chain 4)
|
Goldman
Sachs & Co. LLC
|
|
|
|
10. In case of proxy voting
Name of the proxy holder
|
|
The number and % of voting rights held
|
|
The date until which the voting rights will be held
|
|
11. Additional Information
|
Please note, positions previously reportable are now exempt under
the market making exemption as they are below the 10%
limit.
Please note, the total amount of voting rights has been rounded to
6 decimal places therefore there is a possibility of a rounding
error.
General email contact:
gs-regops-emea-position-enquiries@gs.com
|
12. Date of Completion
|
17-Nov-2023
|
13. Place Of Completion
|
Paris
|